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Abstract 
Purpose: To investigate the effect of Zhen-wu decoction (ZWD) on oxidative stress and hemodynamics 
in chronic congestive heart failure (CHF) rats. 
Methods: After Sprague Dawley (SD) rats were successfully prepared into CHF, they were randomly 
divided into normal control group, model (untreated CHF) group, captopril group, high-dose, middle-
dose and low-dose of ZWD groups, and were treated with drugs for 4 weeks respectively. At the end of 
the experiment, hemodynamic function, whole heart weight index, blood creatinine kinase (CK), 
superoxide dismutase (SOD), malondialdehyde (MDA), nitric oxide (NO) and nitric oxide synthase 
(NOS) were determined. 
Results: Compared with normal control group, ZWD group showed decreased arterial systolic pressure 
(SBP, 89.16 ± 17.27 mmHg), diastolic pressure (DBP, 72.54 ± 22.36 mmHg), mean arterial pressure 
(MAP, 72.64 ± 11.87 mmHg), heart rate (HR, 368.25 ± 39.12 beats/min), left ventricular systolic peak 
(LVSP, 105.27 ± 15.23 mmHg), and left ventricular pressure change rate (dp/dt max) (p < 0.05), while 
left ventricular end diastolic pressure (LVEDP) (19.52 ± 1.89 mmHg), whole heart weight index (2.74 ± 
0.16 mg/g), blood CK (0.98 ± 0.16 U/mL), MDA (17.28 ± 2.94 nmol/mL), NO (36.35 ± 3.27 umol/L), NOS 
(39.89 ± 3.56 U/mL) significantly increased (p < 0.05). High dose of ZWD significantly improved 
hemodynamic function, lowered MDA (8.85 ± 2.14 nmol/mL) and NO (24.25 ± 3.21 umol/L) levels (p < 
0.05), and also decreased CK (0.58 ± 0.37 U/mL) and NOS (26.12 ± 3.87 U/mL) in CHF rats (p < 0.05). 
Conclusion: ZWD improves adriamycin-induced chronic congestive heart failure in rats significantly, 
and therefore has potential to be developed for the management of chronic congestive heart failure. 
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Chronic heart failure (CHF) is a common, 
complex clinical syndrome that arises from 
structural or functional cardiac disorder, including 
changes in electrophysiology, contraction, and 
energy metabolism [1]. Heart failure (HF) is 
becoming an increasing disease with an 
incidence approaching 1 % of the population 
over 65 years of age in developed countries [2]. 
In China, it was reported that the prevalence of 
HF in the adult population from ten provinces 
was 0.9 % [3]. The prognosis for CHF is poor 
and there are few therapeutic options, HF is even 
worse than many types of cancer [4]. 
Furthermore, there has been an increased 
hospitalization burden, and makes HF a global 
public health problem. 
 
The most effective and commonly used drugs for 
treatment of HF are angiotensin-converting 
enzyme (ACE) inhibitors, β-adrenoceptor 
blockers, and digitalis [5-7]. The American Heart 
Association (AHA) and European Society of 
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Cardiology (ESC) have issued and updated the 
guidelines for diagnosis and management of 
CHF [2]. However, HF is still a leading cause of 
death worldwide [8], therefore it is necessary to 
seek novel effective drugs for HF. Traditional 
Chinese Medicine has gained popularity in the 
treatment of complex multifactor diseases by 
targeting multiple pathways to improve 
therapeutic efficacy and could reduce drug-
related side effects and drug resistance. TCMs 
such as Shengmai [9], Sini decoction [10], 
Shuanglong formula [11], and Huangqi injection 
[12] have potential therapeutic effects in the 
treatment of cardiovascular diseases. 
 
Zhen-wu decoction(ZWD) have the effects of 
promoting blood circulation and  removing blood 
stasis, tonifying blood, arresting bleeding, and 
alleviating pain [13,14]. However, to the best of 
our knowledge, no studies on the therapeutic 
effect of Zhen-wu decoction on cardiovascular 
diseases have been reported.  
 
In this work, the effect of ZWD on chronic 
congestive heart failure (CHF) was studied in 




Preparation of Zhen-wu decoction 
 
Zhen-wu decoction was composed of Fuling 
(Poria cocos (Schw.) Wolf) 15 g, Baishao 
(Paeonia lactiflora Pall.) 15 g, Shengjiang 
(Zingiber officinale Roscoe) 15 g, Baizhu 
(Atractylodes macrocephala Koidz.) 10 g, Fupian 
(Aconitum carmichaeli Debx.) 7 g. These herbs 
were mixed, and decocted with 6000 mL of water 
twice, 45 min on each occasion. After filtering 
and concentrating the decoction, the 




SD male rats, weighing (180 ± 20) g, was 
purchased from the Experimental Animal Center 
of Jiangxi Province (Certificate no. SYXK 2006-
0001). Each rat was raised in single cage at a 
temperature of (20 ± 2) oC and relative humidity 
of 55 - 65 %. They were fed on rodent feed and 
had free access to water.  
 
The rat experiment was approved by the Animal 
Care and Use Committee of Jiangxi University of 
Traditional Chinese Medicine (approval ref no. 
20101005) and was carried out in compliance 
with Directive 2010/63/EU on the handling of 
animals used for scientific purposes [15]. 
 
Preparation of chronic heart failure rats and 
treatment 
 
Sixty SD rats were divided into normal control 
group, model (untreated CHF) group, captopril 
group, high-dose, middle-dose and low-dose of 
Zhen-wu decoction groups. There were 10 rats in 
each group. Normal control group was treated 
with intraperitoneal injection of 0.2 mL saline 
once a week. Other rats were administered 
intraperitoneal injection of adriamycin 
hydrochloride (2 mg/kg) once a week for 6 
weeks. Six weeks later, 2 rats were randomly 
selected from the rats which survived heart 
failure while rats without CHF were further 
treated with adriamycin hydrochloride for 4 
weeks. Treatments commenced from the 7th 
week after CHF was established. The rats in the 
normal control group and the model group were 
intragastrically administrated with 2 mL saline, 
once a day; the rats in the ZWD group were 
administered intragastrically ZWD (1.2, 2.4 or 4.8 
g/kg) daily. The rats in the captopril group were 
administered captopril (100 mg/kg) daily. The 
treatment lasted for 4 weeks. 
 
Determination of cardiac function and 
hemodynamics  
 
Twenty four hours after the last intragastrical 
administration, the rats were anesthetized by 
intraperitoneal injection of 20 % urethane 
solution in 6 mL/kg, and were fixed on a table in 
a spinal position. The right common carotid 
artery was separated with a ventricular canula 
(cardiac catheter l mm in diameter), which was 
connected with Biopac multichannel physiologic 
sign collection and processing system via a 
pressure transducer; the SBP, DBP, MAP, HR 
were recorded. The cardiac catheter was slowly 
pushed, and at the same time the pressure 
oscilloscope was observed. If the wave form 
changed and pulse pressure increased, it 
indicates that the cardiac catheter has entered 
into the left ventricle and cannot go further. After 
stabilization for 3 min, LVSP, LVEDP, + dp/dtmax, 
and - dp/dtmax were recorded. For the 
hemodynamic indices, 5 sections were taken for 
calculation of the mean value. Thereafter, 10 mL 
blood was taken from the abdominal aorta, 5 mL 
added with 200 uL EDTANa2 and 5 mL with no 
anti-coagulant, which were centrifuged at 3000 
rpm for 15 min. The plasma and serum were kept 
at -20 oC for other index detection. 
 
Determination of heart weight index  
 
After assessment of hemodynamic function and 
blood sampling, the heart was rapidly separated 
with the blood stain washed with saline and 
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water blotted with a filter paper. The whole heart 
was weighed, and whole heart weight index was 
calculated as the ratio of heart weight (mg) to 




CK, MDA, SOD, NO and NOS in plasma and 
serum were determined according to the 
instructions that accompanied the kits (Shenzhen 





All the data were analyzed using Statistical 
Package SPSS 16.0 (SPSS Inc, Illinois, Chicago, 
USA) and are expressed as mean ± standard 
error of mean (SEM). The data were analyzed by 
one-way analysis of variance (ANOVA) followed 
by Dunnett’s t-test. A value of p < 0.05 was 




Effects of ZWD on whole heart weight index 
of CHF rats   
 
The heart weight index (HWI) of the model group 
was higher than that in the normal control group 
(p < 0.05), indicating that there were myocardial 
hypertrophy or stasis of blood in the model 
group. Compared with model group, HWI was 
not significantly changed in captopril and ZWD 
treatment groups (Table 1). 
 
Table 1: Heart weight index of CHF rats (n = 10) 
 
Group Dose(g/kg) HWI(mg/g) 
Normal - 2.23±0.24* 
Model - 2.74±0.16 
Captopril 0.1 2.46±0.25 
ZWD-L 1.2 2.66±0.37 
ZWD-M 2.4 2.56±0.31 
ZWD-H 4.8 2.52±0.28 
*P < 0.05, **p < 0.01 compared with model group; 
ZWD-L: low dose of ZWD, ZWD-M: medium dose of 
ZWD, ZWD-H: high dose of ZWD 
 
Effect of ZWD on hemodynamic parameters 
in CHF rats  
 
Compared with the normal control group, SBP, 
DBP, MAP, HR, LVSP, dp/dtmax were significantly 
decreased (p < 0.05), and LVEDP was 
significantly increased in the model group (p < 
0.01). ZWD significantly improved vasomotor and 
left ventricular functions of CHF rats (p < 0.05), 
while captopril did not (Table 2 and Table 3). 
 
Effect of ZWD on blood CK, SOD, MDA, NO 
and NOS in CHF rats 
 
Compared with the normal control group, CK and 
NOS activities, MDA and NO levels were 
significantly increased (p < 0.01), 
 
         Table 2: Hemodynamic index of CHF rats (n = 10) 
 
Group Dose (g/kg) SBP (mmHg) SBP (mmHg) MAP (mmHg) HR (beat/min) 
Normal — 121.34±14.25* 102.36±17.35* 108.34±12.46* 435.27±32.41* 
Model — 89.16±17.27 72.54±22.36 72.64±11.87 368.25±39.12 
Captopril 0.1 112.23±25.64 90.24±31.25 99.37±27.25 412.37±53.32 
ZWD-L 1.2 94.38±21.17 79.36±28.46 79.32±17.38 383.43±35.26 
ZWD-M 2.4 108.38±18.27* 95.33±19.65 96.38±15.29 392.35±32.67 
ZWD-H 4.8 125.48±12.52** 100.39±19.38** 107.38±13.83** 426.33±40.67* 
              *P < 0.05, **p < 0.01 compared with model group; ZWD-L: low dose of ZWD, ZWD-M: medium dose  
          of ZWD, ZWD-H: high dose of ZWD 
 
     Table 3: Hemodynamic index of CHF rats (n = 10) 
 
Group Dose (g/kg) 
LVSP 
(mmHg) LVEDP (mmHg) +dp/dtmax -dp/dtmax 
Normal — 146.34±13.65* 7.32±1.35** 3621.35±426.37* 3832.45±425.65* 
Model — 105.27±15.23 19.52±1.89 2236.24±658.91 2436.71±672.36 
Captopril 0.1 112.24±33.65 17.38±2.43 3412.56±835.62 3322.14±721.33 
ZWD-L 1.2 114.33±18.25 17.37±2.12 2673.26±563.21 2638.53±654.83 
ZWD-M 2.4 120.38±16.54* 15.39±2.86 3126.37±497.85* 3267.12±547.35* 
ZWD-H 4.8 141.27±14.27* 10.26±2.43* 3587.26±526.37* 3789.47±524.45* 
*P < 0.05, **p < 0.01 compared with model group; ZWD-L: low dose of ZWD, ZWD-M: medium dose of ZWD, 
ZWD-H: high dose of ZWD 
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Table 4: Blood CK, SOD, MDA, NO and NOS of the rats (n=10) 
 
Group Dose(g/kg) CK(U/mL) SOD(U/mgprot) MDA(nmol/mL) NO(umol/L) NOS (U/mL) 
Normal - 0.42±0.14** 92.31±7.35** 6.14±1.27** 21.26±1.78** 24.41±3.23** 
Model - 0.98±0.16 70.33±3.56 17.28±2.94 36.35±3.27 39.89±3.56 
Captopril 0.1 0.45±0.12** 81.26±8.25 8.11±1.58** 23.44±3.58** 35.64±2.98 
ZWD-L 1.2 0.78±0.24 71.84±7.26 12.36±2.64 31.42±4.22 37.38±4.15 
ZWD-M 2.4 0.63±0.27 74.28±7.32 10.24±2.37 28.38±3.86* 34.43±3.78 
ZWD-H 4.8 0.58±0.37 75.36±6.37 8.85±2.14** 24.25±3.21** 26.12±3.87** 
*P < 0.05, **p < 0.01 compared with model group; ZWD-L: low dose of ZWD, ZWD-M: medium dose of ZWD, 
ZWD-H: high dose of ZWD 
 
and SOD activity was significantly decreased in 
the model group (p < 0.01). Compared with the 
model group, blood CK activity, MDA and NO 
levels were significantly decreased in the 
captopril group (p < 0.01), and MDA and NO 
levels, NOS activity significantly decreased in the 




Hemodynamic parameters are important indices 
reflecting cardiac functions. Zhen-wu decoction 
strengthened the diastolic and contractile 
functions of the artery and left ventricle, and 
significantly improved the left ventricular function 
with no change of heart rate, showing better 
effects than that of captopril.  
 
Oxidative stress is one key factor for heart failure 
[16]. In heart failure, a large quantity of reactive 
oxygen species and nitric oxide are produced. A 
lot of free radicals induce lipid peroxidation, 
injuring the cellular membrane and inducing 
inflammation and cell apoptosis. In the 
physiologic state, the organism has an anti-
oxidation system, for example SOD can clear 
away superoxide anions in time, and reduce lipid 
peroxidation. In physiologic state, NO has the 
function of dilating blood vessels. However, a 
large quantity of NO did not only induce the 
production of free radicals, but also mediated 
serious neurotoxicity and cytotoxicity, promoting 
injury of tissues. Synthesis of NO requires the 
participation of NOS [17]. It was observed that 
ZWD significantly decreased blood MDA and NO 
levels, as well as CK and NOS activities, without 
affecting blood SOD activity. Therefore, it is 
seems that the improvement in oxidative stress 




The findings of this study indicate that ZWD 
improves chronic congestive heart failure in CHF 
model rats, and this is possibly related to the 
alleviation of oxidative stress and improvement in 
left ventricular function. Thus, ZWD has the 
potential to be developed as an alternative 
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